Elevated Matrix Metalloproteinase 9 in Treatment Resistant Bipolar Depression
- 15 June 2023
- journal article
- research article
- Published by Marmara University in Clinical and Experimental Health Sciences
- Vol. 13 (2) , 434-440
Abstract
Objective: Matrix metalloproteinase is a family of proteases with different pathophysiological roles. Matrix metalloproteinase 9 (MMP9) plays an enzymatic role in the restructuring of the extracellular matrix and adhesion molecules. MMP9 is upregulated in pro-inflammatory states and leads to breakdown of tight junctions thereby increasing blood-brain barrier (BBB) permeability. MMP9 may contribute to the pathophysiology of bipolar disorder (BD) via proteolysis of the BBB thus allowing entry of cytokines and neurotoxic agents into CNS. Polymorphisms of the MMP9 gene may pose increased risk for BD and schizophrenia. In this study we sought to determine MMP9 levels in treatment resistant bipolar depressed patients before and after treatment. Methods: Treatment resistant bipolar depressed patients were treated with escitalopram, in combination with the COX-2 inhibitor, celecoxib. It was hypothesized that combination treatment would reverse resistance and augmented treatment responses. This was a 10-week, randomized, double-blind, two-arm, placebo-controlled study. Results: MMP9 levels were higher in bipolar depressed patients compared to healthy controls at baseline, however, the difference did not reach significance. Levels decreased after treatment reaching significance in the escitalopram plus placebo group. Female patients had significantly lower MMP9 levels at end of treatment. MMP9 was higher in carriers the MMP9 SNP, rs3918242, than in noncarriers, but the difference did not reach statistical significance. Conclusion: MMP9 decreased in bipolar depressed patients with treatment. Age, sex and the rs3918242 polymorphism play a role in MMP9 levels. Future studies should confirm the role of MMP9 in the pathogenesis and pathophysiology of bipolar disorder, as a potential diagnostic biomarker.Keywords
This publication has 20 references indexed in Scilit:
- The global prevalence of common mental disorders: a systematic review and meta-analysis 1980–2013International Journal of Epidemiology, 2014
- Impaired functioning in euthymic patients with bipolar disorder — HSV-1 as a predictorProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2012
- Plasma Protein Biomarkers for Depression and Schizophrenia by Multi Analyte Profiling of Case-Control CollectionsPLOS ONE, 2010
- White matter abnormalities in bipolar disorder: insights from diffusion tensor imaging studiesJournal of Neural Transmission, 2010
- Matrix Metalloproteinase-9 (MMP9)—A Mediating Enzyme in Cardiovascular Disease, Cancer, and Neuropsychiatric DisordersCardiovascular Psychiatry and Neurology, 2009
- Matrix Metalloproteinase-9 Gene and Bipolar Mood DisorderNeuroMolecular Medicine, 2009
- Plasma Levels of Matrix Metalloproteinase-9 are Independently Associated With Psychosocial Factors in a Middle-Aged Normal PopulationPsychosomatic Medicine, 2009
- Oligodendroglial abnormalities in schizophrenia, mood disorders and substance abuse. Comorbidity, shared traits, or molecular phenocopies?International Journal of Neuropsychopharmacology, 2007
- The Psychopathology and Treatment of Bipolar DisorderAnnual Review of Clinical Psychology, 2006
- Matrix Metalloproteinase-9 Is Required for Hippocampal Late-Phase Long-Term Potentiation and MemoryThe Journal of Neuroscience, 2006